Palvella Therapeutics' stock surged 6.05% during intraday trading on Friday, driven by a wave of positive analyst sentiment.

Multiple Wall Street analysts expressed bullish views on the healthcare company. Oppenheimer maintained a Buy rating on Palvella Therapeutics with a price target of $210.00, highlighting confidence in the company's prospects.

The overall optimism from the analyst community regarding top healthcare stocks, including Palvella Therapeutics, appears to have fueled investor buying interest, contributing to the significant price appreciation during the session.